diff --git a/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md b/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
index 253a7b092..dba808af0 100644
--- a/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
+++ b/inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
@@ -66,6 +66,6 @@ intake_tier: research-task
 **Context:** Cocaine use disorder is the highest-unmet-need SUD category. Two Phase 2 trials recruiting as of early 2025. No completed results. This archive serves as a tracking record for the extractor to know: don't extract efficacy claims yet, revisit when trial results publish.
 
 ## Curator Notes (structured handoff for extractor)
-PRIMARY CONNECTION: [[GLP-1 receptor agonists reduce substance use disorder risk by 40-75%]] (if this claim exists or is proposed from Session 39 sources)
+PRIMARY CONNECTION: GLP-1 receptor agonists reduce substance use disorder risk by 40-75% (if this claim exists or is proposed from Session 39 sources)
 WHY ARCHIVED: Tracking the CUD trial status so future Vida sessions know exactly where the evidence stands — no completed RCT, two Phase 2 recruiting, check back 2027.
 EXTRACTION HINT: Do NOT extract efficacy claims. Extract only: (1) the status fact that no pharmacotherapy exists for CUD and (2) the trial pipeline status. The All of Us OR=0.25 should be cited as the observational basis, with confidence flagged as experimental pending RCT.